This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are reviewed, showing associations between treatment and increased serum TTR levels, delayed time to first cardiovascular hospitalization, reduced NT-proBNP levels, and lower all-cause mortality. These results suggest a clinically meaningful benefit of acoramidis and support its potential role in managing ATTR-CM.